Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Phytomedicine ; 64: 153084, 2019 Sep 05.
Artigo em Inglês | MEDLINE | ID: mdl-31514083

RESUMO

BACKGROUND: Metastasized melanoma is extremely difficult to treat. Activation of C-C chemokine receptor type 7 (CCR7) has been linked to melanoma metastasis. CCR7 can be directly regulated by miR-let-7. We have previously shown that an ethanolic extract of an herbal formula comprising Sophorae Flos and Lonicerae Japonicae Flos (SLE) inhibits melanoma cell migration and invasion. PURPOSE: In this study, we determined whether SLE suppresses melanoma metastasis, and whether regulation of miR-let-7a/f-CCR7 signaling is involved in the effect. STUDY DESIGN AND METHODS: Small RNA sequencing was conducted to compare miRNA expression profiles of B16F10 tumors dissected from SLE-treated or untreated mice. Western blot and RT-qPCR analyses were employed to examine protein and miRNA levels, respectively. A B16F10 melanoma lung metastasis mouse model was used to evaluate the effects of SLE on melanoma metastasis. MiR-let-7a/f-knockdown and CCR7-overexpression cell models were used to investigate the involvement of miR-let-7a/f-CCR7 signaling in the anti-metastatic effects of SLE. RESULTS: It was found that SLE upregulated levels of miR-let-7a/f in B16F10 melanoma tissues. SLE significantly elevated levels of miR-let-7a/f, lowered the protein level of CCR7, inhibited the phosphorylation of CCR7 downstream molecules p38 and JNK in B16F10 and A375 melanoma cells. SLE inhibited B16F10 melanoma lung metastasis in mice. SLE upregulated levels of miR-let-7a/f, and lowered protein levels of CCR7, MMP-2, MMP-9, phospho-p38 (Thr180/Tyr182) and phospho-JNK (Thr183/Tyr185) in melanoma-invaded lung tissues. Knockdown of miR-let-7a/f diminished the effects of SLE on CCR7 signaling in, and invasion of, melanoma cells. Overexpression of CCR7 lessened the effects of SLE in inhibiting the phosphorylation of p38 and JNK in, and the invasive capability of, melanoma cells. CONCLUSION: We for the first time demonstrated that SLE inhibits melanoma metastasis in mice, and that regulation of the miR-let-7a/f-CCR7 pathway contributes to the anti-metastatic mechanisms of SLE. These findings provide a pharmacological basis for developing SLE as a modern agent for treating metastatic melanoma. Additionally and importantly, this study suggests that regulating the miR-let-7a/f-CCR7 pathway is a novel strategy for controlling melanoma metastasis.

2.
Int J Med Sci ; 16(5): 729-740, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31217741

RESUMO

Cataracts are the major cause of blindness and are associated with oxidative damage of the lens. In the present study, the aim was to evaluate the protective effects of rosmarinic acid on selenite-induced cataractogenesis in Sprague-Dawley rat pups. The animals were randomly divided into five groups, each of which consisted of 10 rat pups. Group I served as normal control (vehicle administration). For testing cataract induction, animals of Groups II, III, IV, and V were administered a single subcutaneous injection of sodium selenite (2.46 mg/kg body weight) on postpartum day 12. After sodium selenite intoxication, Group II served as control selenite. From the 11th day through the 17th day, Groups III-V received rosmarinic acid intraperitoneally at doses of 5, 10, and 50 mg/kg, respectively. On postpartum day 24, the rat pups were examined for cataract formation, and the lenses were isolated for further analysis of proteins and oxidative damage indicators. Selenite caused significant (p < 0.05) cataract formation. Through the effects of selenite, the protein expressions of filensin and calpain 2 were reduced, and the calcium concentrations, the level of lipid peroxidation (TBARS), and inflammation indicators (iNOS, COX-2, and NFκB) were upregulated. Furthermore, the protein expression of the antioxidant status (Nrf2, SOD, HO-1, and NQO1), the antioxidant enzymes activities (GSH-Px, GSH-Rd, and catalase), and the GSH levels were downregulated. In contrast, treatment with rosmarinic acid could significantly (p < 0.05) ameliorate cataract formation and oxidative damage in the lens. Moreover, rosmarinic acid administration significantly increased the protein expressions of filensin, calpain 2, Nrf2, SOD, HO-1, and NQO1, the antioxidant enzymes activities, and the GSH level, in addition to reducing the calcium, lipid peroxidation, and inflammation indicators in the lens. Taken together, rosmarinic acid is a prospective anti-cataract agent that probably delays the onset and progression of cataracts induced by sodium selenite.

3.
Carbohydr Polym ; 212: 215-221, 2019 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-30832850

RESUMO

DrzBC and DrzBS (10-23 DNAzyme) could block the expression of HBV e- and s- gene respectively. But the application of 10-23 DNAzyme was limited owing to the lack of appropriate delivery vehicles. Chitosan oligosaccharide-SS-Octadecylamine (CSSO), a redox-responsive nano-sized polymeric carrier, could self-aggregate and bind with DNA by electrostatic interaction at proper mass ratio. Compared with the traditional commercial carrier Lipo2000, CSSO exhibited lower cytotoxicity, efficient cellular uptake by targeting cells, and rapidly DNA released in cytoplasm after escaping from endosomes. Including the same DNA concentration, Lipo2000/(DrzBC or DrzBS) showed maximum inhibitory rate on HBeAg (47.29 ±â€¯1.86%) and HBsAg (33.58 ±â€¯0.72%) secretion after 48 h incubation, and then both decreased. In contrast, HBeAg secretion inhibition by CSSO/DrzBC and HBsAg secretion inhibition by CSSO/DrzBS were up to 73.86 ±â€¯1.77% and 67.80 ±â€¯2.51% at 48 h, and further increased to 83.83 ±â€¯2.34% and 76.79 ±â€¯2.18% at 72 h, respectively. CSSO is a promising redox-responsive polymeric carrier for efficient anti-Hepatitis B Virus gene therapy.


Assuntos
Aminas/administração & dosagem , Quitosana/administração & dosagem , Terapia Genética/métodos , Vírus da Hepatite B/efeitos dos fármacos , Oligossacarídeos/administração & dosagem , Polímeros/administração & dosagem , Aminas/metabolismo , Quitosana/metabolismo , DNA Viral/efeitos dos fármacos , DNA Viral/genética , DNA Viral/metabolismo , Relação Dose-Resposta a Droga , Portadores de Fármacos/administração & dosagem , Portadores de Fármacos/metabolismo , Células Hep G2 , Vírus da Hepatite B/genética , Vírus da Hepatite B/metabolismo , Humanos , Oligossacarídeos/metabolismo , Oxirredução/efeitos dos fármacos , Polímeros/metabolismo
4.
Int J Pharm ; 557: 170-177, 2019 Feb 25.
Artigo em Inglês | MEDLINE | ID: mdl-30597264

RESUMO

Because numerous challenges limit the effective oral delivery of protein and peptide drugs, we developed promising chitosan (CS)-modified, dual drug-loaded nanoparticles (NPs) simultaneously containing salmon calcitonin (sCT) and puerarin (PR) (CS-sCT/PR-NPs), and to explore the potential of PR as a protease inhibitor. This oral delivery system showed efficient encapsulation of sCT (75.7%) and PR (50.9%), protection of encapsulated sCT and PR from premature release in simulated gastric fluid (SGJ, pH 1.2), and sustained-release behavior in phosphate buffer saline (PBS, pH 7.4). CS-sCT/PR-NPs were capable of sequential drug-release in which PR was partially released prior to sCT, allowing PR to play a role of enzyme inhibitor before sCT release. Compared with CS-sCT-NPs, CS-sCT/PR-NPs were more stable in simulated intestinal fluid containing pancreatinum. The internalization of fluorescein isothiocyanate-labeled sCT (FITC-sCT) by Caco-2 cells increased when incorporated into NPs compared with free sCT. In vivo, the oral absolute bioavailability of sCT in CS-sCT/PR-NPs was 12.52 ±â€¯1.83%, approximately 1.74-fold higher than that of the NPs not co-loaded with PR. In conclusion, the CS-based NPs and introduction of PR as a protease inhibitor improved the oral bioavailability of sCT and had potential to be developed as an oral delivery system of peptide drug.


Assuntos
Calcitonina/administração & dosagem , Quitosana/administração & dosagem , Portadores de Fármacos/administração & dosagem , Isoflavonas/administração & dosagem , Nanopartículas/administração & dosagem , Administração Oral , Animais , Disponibilidade Biológica , Células CACO-2 , Calcitonina/química , Calcitonina/farmacocinética , Sobrevivência Celular/efeitos dos fármacos , Quitosana/química , Quitosana/farmacocinética , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Liberação Controlada de Fármacos , Humanos , Absorção Intestinal , Secreções Intestinais/química , Isoflavonas/química , Isoflavonas/farmacocinética , Nanopartículas/química , Ratos Sprague-Dawley
5.
Sci Rep ; 8(1): 4277, 2018 Mar 09.
Artigo em Inglês | MEDLINE | ID: mdl-29523860

RESUMO

Autism spectrum disorder (ASD) is a highly prevalent neurodevelopmental disorder, and the exact causal mechanism is unknown. Dysregulated allele-specific expression (ASE) has been identified in persons with ASD; however, a comprehensive analysis of ASE has not been conducted in a family quartet with ASD. To fill this gap, we analyzed ASE using genomic DNA from parent and offspring and RNA from offspring's postmortem prefrontal cortex (PFC); one of the two offspring had been diagnosed with ASD. DNA- and RNA-sequencing revealed distinct ASE patterns from the PFC of both offspring. However, only the PFC of the offspring with ASD exhibited a mono-to-biallelic switch for LRP2BP and ZNF407. We also identified a novel site of RNA-editing in KMT2C in addition to new monoallelically-expressed genes and miRNAs. Our results demonstrate the prevalence of ASE in human PFC and ASE abnormalities in the PFC of a person with ASD. Taken together, these findings may provide mechanistic insights into the pathogenesis of ASD.

6.
Anal Chem ; 88(2): 1195-201, 2016 Jan 19.
Artigo em Inglês | MEDLINE | ID: mdl-26674846

RESUMO

Dramatic photochromic-change of 2,5-bis(triphenylamine)-substituted N,N'-diphenylpyrrolo-[3,2-b]pyrrole (1) with halocarbons provides an effective route for halocarbon analysis with the naked eye. The visual detection range can reach as low as 10(-4) ∼ 10(-5) M (1-10 ppm) in CH3CN. This method can also be applied for detection of CHCl3 in water. Fabrication of a disposable paper test cartridge along with using a camera flash as the light source allows on-site halocarbon detection in seconds. Quantitative analysis for CHCl3 and CH2Cl2 have also been demonstrated.


Assuntos
Hidrocarbonetos Halogenados/análise , Pirróis/química , Processos Fotoquímicos
7.
CNS Neurosci Ther ; 21(3): 271-9, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25495836

RESUMO

AIM: Lactates accumulate in ischemic brains. G protein-coupled receptor 81 (GPR81) is an endogenous receptor for lactate. We aimed to explore whether lactate is involved in ischemic injury via activating GPR81. METHODS: N2A cells were transfected with GFP-GPR81 plasmids 24 h previously, and then treated with GPR81 antagonist 3-hydroxy-butyrate (3-OBA) alone or cotreated with agonists lactate or 3, 5-dihydroxybenzoic acid (3, 5-DHBA) during 3 h of oxygen-glucose deprivation (OGD). Adult male C57BL/6J mice and primary cultured cortical neurons were treated with 3-OBA at the onset of middle cerebral artery occlusion (MCAO) or OGD, respectively. RESULTS: The GPR81 overexpression increased the cell vulnerability to ischemic injury. And GPR81 antagonism by 3-OBA significantly prevented cell death and brain injury after OGD and MCAO, respectively. Furthermore, inhibition of GPR81 reversed ischemia-induced apoptosis and extracellular signal-regulated kinase (ERK) signaling may be involved in the neuroprotection. CONCLUSIONS: G protein-coupled receptor 81 (GPR81) inhibition attenuated ischemic neuronal death. Lactate may aggravate ischemic brain injury by activating GPR81. GPR81 antagonism might be a novel therapeutic strategy for the treatment of cerebral ischemia.


Assuntos
Isquemia Encefálica/fisiopatologia , Ácido Láctico/metabolismo , Receptores Acoplados a Proteínas-G/antagonistas & inibidores , Ácido 3-Hidroxibutírico/farmacologia , Animais , Isquemia Encefálica/tratamento farmacológico , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Hipóxia Celular/efeitos dos fármacos , Hipóxia Celular/fisiologia , Linhagem Celular Tumoral , Células Cultivadas , Fármacos do Sistema Nervoso Central/farmacologia , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/fisiopatologia , Modelos Animais de Doenças , Glucose/deficiência , Hidroxibenzoatos/farmacologia , Infarto da Artéria Cerebral Média , Ácido Láctico/administração & dosagem , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Fármacos Neuroprotetores/farmacologia , Ratos Sprague-Dawley , Receptores Acoplados a Proteínas-G/agonistas , Receptores Acoplados a Proteínas-G/metabolismo , Resorcinóis/farmacologia
8.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 41(4): 393-401, 2012 Jul.
Artigo em Chinês | MEDLINE | ID: mdl-22927074

RESUMO

OBJECTIVE: To assess the neuroprotective effects of ginsenoside Rg1 against ß-amyloid peptide (Aß(25-35))-induced apoptosis in primarily cultured rat cortical neurons. METHODS: Primarily cultured cortical neurons were obtained from embryonic (E18d) rat fetus and maintained in neurobasal medium for 7d. Primary neurons pretreated with 1 µmol/L, 10 µmol/L or 20 µmol/L Rg1 for 24 h were challenged with 10 µmol/L Aß(25-35) for 72 h. Morphological changes of neurons were evaluated; mitochondrial membrane potential (ΔΨm) was measured; with JC-1 staining and the expression of neural apoptosis-related proteins was detected by Western blot analysis. RESULTS: Exposure to Aß(25-35) for 72 h caused serious neural cell insults. A pretreatment with Rg1 significantly reduced Aß(25-35)induced cell death in a dose-dependent manner, with a maximal effect (-90%) obtained at 20 µmol/L. The JC-1 staining results demonstrated the loss of ΔΨm after Aß(25-35) treatment, while Rg1 maintained the normal level of ΔΨm. A series of mitochondrion-mediated apoptotic events happened after Aß(25-35) treatment, such as decrease of Bcl-2/Bax, release of cytochrome C and activation of caspase 9 and caspase 3, which were all blocked by Rg1 pretreatment. Both estrogen receptor (ER) antagonist ICI182, 780 and glucocorticoid receptor (GR) antagonist RU486 blocked the antiapoptotic effects of Rg1. CONCLUSION: Ginsenoside Rg1 protects primary cultured rat cortical neurons from Aß(25-35)-induced injury, which may be associated with mitochondrion-mediated antiapoptosis pathway.


Assuntos
Peptídeos beta-Amiloides/toxicidade , Apoptose/efeitos dos fármacos , Ginsenosídeos/farmacologia , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Fragmentos de Peptídeos/toxicidade , Animais , Caspase 3/metabolismo , Caspase 9/metabolismo , Células Cultivadas , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Córtex Cerebral/patologia , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Mitocôndrias/fisiologia , Neurônios/metabolismo , Neurônios/patologia , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Ratos , Ratos Sprague-Dawley , Proteína X Associada a bcl-2/metabolismo
9.
Zhonghua Liu Xing Bing Xue Za Zhi ; 31(6): 692-5, 2010 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-21163106

RESUMO

OBJECTIVE: To assess the impact on caretaker who looked after patients with Parkinson's disease (PD) and to identify the main factors related to their burden. METHODS: 115 consecutive pairs of PD patients and their caretakers were included. Caregiver Burden Inventory (CBI) was used to assess the burden of PD on the caretakers. Patients were evaluated by neurologists using the United Parkinson's Disease Rating Scale (UPDRS), the Hoehn and Yahr Scale (H-Y Scale), the Activity of Daily Living Scale (ADL), the Parkinson's Disease Questionnaire (PDQ-39), the Hamilton Depression Rating Scale (HAMD), the Hamilton Anxiety Rating Scale (HAMA), the Montreal Cognitive Assessment (MoCA) and the Mini-mental State Examination (MMSE). Multiple linear stepwise regression models were fitted to ascertain the factors linked to the CBI. RESULTS: Based on multiple linear stepwise regression analysis, ADL (ß = -0.813, t = -6.265, P = 0.000) and PDQ-39 (ß = 0.285, t = 4.256, P = 0.000) of patients and the age of caretakers (ß = 0.327, t = 3.107, P = 0.002) proved to be the main predictors of CBI. CONCLUSION: Many factors might comprehensively affect the burden of PD on caretakers of the patients. Attention needs to be given to the early identification of factors that generating stress on caretakers in order to improve their quality of life.


Assuntos
Cuidadores/psicologia , Doença de Parkinson , Qualidade de Vida , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estresse Psicológico , Inquéritos e Questionários
10.
J Cell Biochem ; 109(3): 498-508, 2010 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-19998413

RESUMO

Relatively little is known about mitochondria metabolism in differentiating embryonic stem (ES) cells. Present research focused on several elements of cellular energy metabolism in hepatic-like tissue derived from mouse ES cells. We demonstrated that mitochondrial location patterns and mitochondrial membrane potential (DeltaPsi(m)) existed in subsequent differentiation of the tissue. Mitochondriogenesis appeared at the early stage and kept a normal DeltaPsi(m) in differentiated mature hepatocytes. Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) expression was transitorily increased at the beginning, and kept a relatively low level later, which accompanied by expression of PPAR-gamma coactivator (PGC)-1alpha, a master regulator of mitochondrial biogenesis. PPAR-beta expression showed robust up-regulation in the late differentiation course. Enhanced co-expressions of PPAR-beta and albumin with catalysis of UDP-glucuronosyltransferases (UGTs) were observed at mature stage. While PPAR-gamma expression changed little before and after differentiation. Mitochondriogenesis could be accelerated by PPAR-alpha specific agonist WY14643 and abolished by its antagonist GW6471 at the early stage. Neither of them affected mitochondrial DeltaPsi(m) and albumin generation in the differentiated hepatocytes. Furthermore, maturation of hepatic-like tissue and mitochondriogenesis in hepatocyte could be efficiently stimulated by PPAR-beta specific agonist L165041 and abolished by PPAR-beta specific antagonist GSK0660, but not affected by PPAR-gamma specific agonist GW1929. In conclusion, the derived hepatic tissue morphologically possessed cellular energy metabolism features. PPAR-alpha seemed only necessary for early mitochondriogenesis, while less important for DeltaPsi(m) retention in the mature tissue derived. The stimulation of PPAR-beta but not -gamma enhanced hepatogenesis, hepatocytes maturation, and mitochondriogenesis. PPAR-beta took an important role in cellular energy metabolism of hepatogenesis.


Assuntos
Células-Tronco Embrionárias/citologia , Hepatócitos/metabolismo , Mitocôndrias/fisiologia , PPAR beta/metabolismo , Animais , Diferenciação Celular , Células Cultivadas , Células-Tronco Embrionárias/metabolismo , Hepatócitos/citologia , Fígado/metabolismo , Potenciais da Membrana , Camundongos , Organogênese/fisiologia , PPAR beta/antagonistas & inibidores , PPAR beta/genética
11.
Zhonghua Yi Xue Za Zhi ; 89(7): 438-44, 2009 Feb 24.
Artigo em Chinês | MEDLINE | ID: mdl-19567089

RESUMO

OBJECTIVE: To investigate the impact of dopaminergic therapy on the onset of motor complications in Parkinson's disease (PD). METHODS: Two clinical questions were identified. (1) Whether levodopa (LD) dose, LD treatment duration, the time from disease onset to initiation of LD can predict the onset of motor complications in PD? and (2) whether dopamine agonists (DA) used in de novo patients can delay the onset of motor complications? Literatures on observation studies of factors associated with motor complications and randomized controlled trials (RCTs) of DA compared to LD in treatment of de novo patients published before May 2008 were retrieved from Pubmed, EMbase, and Cochrane Database. Methodology quality was critically assessed. RESULTS: 12 articles on the first question were selected, including one RCT, five cohort studies, six case-control studies. Six RCTs on the second question were selected. Because of clinical heterogeneity among the researches thus retrieved, meta-analysis was not conducted, and qualitative analysis showed that initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose might be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications. DA as initial treatment was associated with later occurrence of dyskinesias (CALM-PD: HR = 0.37, 95% CI: 0.25 - 0.56, P < 0.001; PELMOPET: HR = 0.48, 95% CI = 0.29 - 0.80, P < 0.001; Ropinirole 056: HR = 0.4, 95% CI: 0.2 - 0.8, P = 0.007; REAL-PET: HR = 8.28, 95% CI: 2.46 - 27.93, P < 0.001). The relationship between LD treatment duration and motor complications could not be concluded from present evidence. CONCLUSION: Initial LD dose, LD dose per kilogram body weight, accumulated LD dose, and accumulated LD equivalent dose may be independent factors associated with motor complications. The time from disease onset to initiation of LD was not correlated with motor complications.


Assuntos
Antiparkinsonianos/uso terapêutico , Discinesias/tratamento farmacológico , Levodopa/uso terapêutico , Doença de Parkinson/tratamento farmacológico , Antiparkinsonianos/administração & dosagem , Discinesias/etiologia , Humanos , Levodopa/administração & dosagem , Doença de Parkinson/complicações , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
12.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 38(3): 242-8, 2009 May.
Artigo em Chinês | MEDLINE | ID: mdl-19504631

RESUMO

OBJECTIVE: To investigate the transcription of cytoskeleton protein genes in differentiation of neurons from mouse embryonic stem (ES) cells induced by all-trans retinoic acid (RA), and to explore the possibility of setting up a method to screen small molecules with promoting or inhibiting effect. METHODS: The hanging drop method was employed for embryonic body formation to mimic embryo development in vivo. Reverse transcriptase PCR (RT-PCR) was performed to investigate mRNA expression of the neuron-specific cytoskeleton proteins including Mtap2, Nefm and beta-tubulin III which were regarded as the inducing effect indexes of RA. Morphological evaluation and immunocytochemistry staining were conducted to identify the neural derivatives. Moreover, the inducing effects of six synthetic molecules were further evaluated. RESULT: RA up-regulated the mRNA expression of Mtap2 and Nefm, especially Mtap2 increased by 1.27 times, which was consistent with the morphological alteration. However, there was no significant changes of beta-tubulin III expression. With addition of the six synthetic molecules, the transcription of Mtap2 was inhibited, while the Nefm mRNA expression was up-regulated in some degree, especially for molecule 1 and 3 that was increased by 1.4 and 1.2 times, which, however, was not parallel to the morphological changes. CONCLUSION: The transcriptional levels of Mtap2 and Nefm are both up-regulated in the RA-induced differentiation of ES cells towards neurons. The up-regulation of Mtap2 is consistent with the morphological alteration, which might be the key landmark in the RA-induced differentiation of ES cells into neurons.


Assuntos
Diferenciação Celular/efeitos dos fármacos , Proteínas do Citoesqueleto/genética , Células-Tronco Embrionárias/citologia , Neurônios/citologia , Tretinoína/farmacologia , Animais , Células Cultivadas , Regulação da Expressão Gênica no Desenvolvimento , Camundongos , Proteínas Associadas aos Microtúbulos/farmacologia , Proteínas de Neurofilamentos/farmacologia , Transcrição Genética , Tubulina (Proteína)/farmacologia
13.
Zhonghua Yi Xue Za Zhi ; 88(21): 1442-5, 2008 Jun 03.
Artigo em Chinês | MEDLINE | ID: mdl-18953846

RESUMO

OBJECTIVE: To survey the prevalence and distribution of neuropsychiatric problems in patients with Parkinson's disease (PD), and to investigate their effects on life quality and the interactions among different neuropsychiatric problems. METHODS: Unified Parkinson's disease rating scale (UPDRS) part III, dyskinesia and motor fluctuation subscale of UPDRS part IV, mini-mental state examination (MMSE) ,Montreal Cognitive Assessment (MoCA), Hamilton rate scale of depression (HRSD), Hamilton anxiety scale (HAMA), digit span (DS), and 39 item Parkinson's disease questionnaire (PDQ-39) were used to assess the motor symptoms and neuropsychiatric problems in 116 PD patients, 66 males and 50 females, aged (67 +/- 9) (50-90), with the course of disease of 5 +/- 4 years (0.5--18 years). Spearman rank order correlation and hierarchical regressions of the major statistical procedures were employed. RESULTS: Various neuropsychiatric problems were found in the PD patients. The neuropsychiatric problems, such as depression, anxiety, apathy, attention deficit disorder, and cognitive deficits, were correlated with the UPDRS III score and Hoehn-Yahr stage, but not correlated with the course of disease ( all P > 0.05). Hallucination was not correlated with any factors (all P > 0.05). There were some correlations among different neuropsychiatric problems. Hierarchical regression revealed that different neuropsychiatric problems showed significant effects on the quality of life after controlling the motor symptoms. Depression (deltaR2 = 19.1%, P < 0.01) and apathy (deltaR2 = 17.0%, P < 0.01) exerted the most powerful influence in causing poor quality of life. CONCLUSION: Neuropsychiatric problems are common a in PD patients Their effects on the poor quality of life are no less than that of motor symptoms and should be recognized and treated well.


Assuntos
Transtorno Depressivo/psicologia , Doença de Parkinson/psicologia , Qualidade de Vida , Idoso , Idoso de 80 Anos ou mais , Transtorno Depressivo/etiologia , Feminino , Humanos , Masculino , Entrevista Psiquiátrica Padronizada , Pessoa de Meia-Idade , Doença de Parkinson/complicações , Escalas de Graduação Psiquiátrica , Análise de Regressão , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA